Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Scientific Advisor Laurence J. N. Cooper, PhD, MD, Presented Today at Aldevron’s Virtual Breakthrough Speakers Series
Presentation Highlights Ziopharm’s Suite of Cellular Therapy Technologies BOSTON , April 28, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper , PhD, MD, Scientific Advisor to the Company, was the inaugural
View HTML
Toggle Summary Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
BOSTON and HOUSTON and TAIPEI, Taiwan , April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being
View HTML
Toggle Summary Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting
Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers BOSTON and HOUSTON , April 07, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today it will be
View HTML
Toggle Summary Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results
Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper ; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory Role James Huang Appointed Executive Chairman and Board Refreshment Completed FDA IND Clearance
View HTML
Toggle Summary Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021
Company to Hold R&D Day on Thursday, March 11, 2021 BOSTON , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on
View HTML
Toggle Summary Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors
BOSTON , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and
View HTML
Toggle Summary Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of
View HTML
Toggle Summary Ziopharm to Participate in Upcoming January Conferences
BOSTON , Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C.
View HTML
Toggle Summary Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer – BOSTON , Dec.
View HTML
Toggle Summary Ziopharm Comments on Consent Solicitation Results
Jaime Vieser and Holger Weis Elected to Board of Directors BOSTON , Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset
View HTML